patients receiving 45 mg and 76.9% of those receiving 90 mg experienced a reduction of 5 points in DLQI score, signifying an important difference, compared with 21.4% for placebo (each p < 0.001 versus placebo). All DLQI scores improved from baseline to Week 12 in each active treatment group compared with placebo (each p < 0.001 versus placebo). Improvements were observed in clinical parameters, HADS, and WLQ.

CONCLUSION: Ustekinumab resulted in significant and clinically meaningful improvements in QOL within 1 month after starting treatment; improvements at Week 12 were maintained through Week 24. Improvements were also observed in anxiety, depression, and work limitations.

**ASSESSMENT OF QUALITY OF LIFE IN DAILY CLINICAL DERMATOLOGICAL ROUTINE: QUESTIONNAIRES AND CHECKLIST**

**OBJECTIVE:** Patient-reported outcome measures, in particular those evaluating health-related quality of life (HRQoL), have been proposed as a mean of facilitating doctor-patient communication. While these measures are commonly included in clinical research studies, their use in clinical practice is still quite limited. Our objective is to assess HRQoL in a dermatological clinic daily routine and to develop an appropriate and effective reporting tool for health personnel. **METHODS:** First phase: patients were invited to complete the Skinindex-29, GHQ-12, and SF-36 questionnaires. Scores were returned to the clinical staff. Second phase: the patients’ medical records were reviewed to verify which issues (e.g., pain, itch, bleeding, sleep loss, functional limitations, fatigue) highlighted by the questionnaires were recorded/neglected by physicians. Third phase: we developed a checklist (presence/absence) of symptoms, emotions or functional problems to be filled by health personnel to complete the routine clinical records. **RESULTS:** For 170 participants (63% males, 35% age > 64 years), feedback forms were provided within three hours from data collection. We analyzed data for 126 patients with the most common conditions: psoriasis (n = 40), dermatitis (n = 30), leg ulcers (n = 13), pemphigus (n = 22), cutaneous lymphoma (n = 21). Overall, sensitivity of medical records in identifying patients’ problems ranged from zero for most issues (including sleep loss, sex life, bleeding), to 3% for burning, 10% for depression, 15% for pain, and 35% for itching. A 30-item checklist (a synthesis of the three questionnaires) was developed and tested in 100 patients who completed their Skinindex-29 questionnaire. The sensitivity and specificity of physicians’ records increased for each issue, ranging from 7% (humiliation) to 81% (itching). **CONCLUSION:** The routine assessment of HRQoL in dermatology is feasible. The checklist induced the staff to report on medical records often-neglected patients’ problems. The checklist increased substantially the sensitivity of physicians in identifying patients’ problems.

**INTERNATIONAL DEVELOPMENT OF THE FIRST QUALITY OF LIFE INSTRUMENT SPECIFIC TO COSMETOLOGY AND PHYSICAL APPEARANCE: THE BEAUTYQOL INITIATIVE**

**OBJECTIVE:** To develop an internationally validated Quality of Life (QoL) instrument specific to cosmetology and personal appearance. This instrument will allow to measure the impact of the use of cosmetic products in various QoL dimensions. **METHODS:** Several studies have demonstrated the positive impact of cosmetic products in dimensions. However, no specific instrument exists to assess the main QoL dimensions in the general population of cosmetic users. The BeautyQol questionnaire is designed to be a multi-dimensional, self-administered QoL questionnaire developed simultaneously in 13 countries. The questionnaire focuses on concerns identified by users using cosmetic products or cosmetic techniques. Semi directive interviews were carried out simultaneously in 10 countries with a total of 309 users by clinical psychologists in France (32), UK (18), Germany (46), Spain (27), Sweden (19), Russia (16), USA (53), Brazil (32), Japan (48), and China (18). Interviews have been audio or video recorded and reported in a standard format report. Interviews were analyzed both semantically and using text-mining techniques (Alceste software). **RESULTS:** From the analysis of the 10 interview country reports, 61 items were selected leading to 61 questions in the prototype questionnaire describing major domains such as well being, self esteem, social life, love life, sexual life, confidence, happiness, image, status, emotion, seduction, success, vitality, charisma, motivation, joy, fun, dignity, etc. Three additional countries joined the project (India, South Africa and Italy). The acceptability study is currently in progress with 650 users. The planned validation study...
Abstracts

will include a minimum of 2600 users worldwide. CONCLUSION: BeautyQol is the first and, to date, the only user centered instrument specific in cosmetology that is being developed simultaneously in 13 countries. BeautyQol is going to be a very valuable tool for national and international assessment of various cosmetic strategies.

**QUALITY OF LIFE IN PATIENTS WITH VITILIGO. USE OF SINGLE ITEM ANALYSIS**

*Sampogna F1, Tabolli S2, Raskovic D1, Guerra L1, Abeni D1*

1IDI IRCCS, Rome, Italy, 2IDI IRCCS, ROME, Italy

Quality of life (QoL) in patients with dermatological conditions is evaluated using generic and specific instruments. Even though these instruments are created to give as a result one or more total scores, the analysis of the answers to the single items may give important information on QoL impairment of patients.

**OBJECTIVES:** To investigate the QoL of patients with vitiligo, also analyzing single questions from a QoL instrument.

**METHODS:** Single items from the Skindex-29 questionnaire, a QoL dermatology-specific instrument, were analyzed in 181 patients with vitiligo. Answers to the Skindex-29 items were given on a 5-point scale, from “never” to “all the time”.

**RESULTS:** The QoL problems more frequently experienced often or all the time were: worry of the disease getting worse (60%), or being a serious condition (40%), anger (37%), embarrassment (34%), depression (31%), affect on having social life affected (28%), and shame (28%). The association of QoL impairment with the probable presence of depression or anxiety, evaluated using the 12-item General Health Questionnaire (GHQ-12), was very strong for all the items, and remained significant also when taking into account simultaneously gender, age, clinical severity, family history, and localization of vitiligo.

**CONCLUSION:** The answers to single items from a dermatology-specific quality of life questionnaire may provide clinicians with relevant additional information on the physical and mental health status of patients.

**THE IMPACT OF GLAUCOMA ON QUALITY OF LIFE: COMPARISON WITH THE CHRONIC DISEASES OSTEoporosis, TYPE 2 DIABETES MELLITUS, AND DEMENTIA**

Wait JG1, Mills T2, Hansen JE1

1Allergan Inc, Irvine, CA, USA, 2Wolters Kluwer Health, Chester, UK

**OBJECTIVE:** Chronic diseases have a long-term negative impact on quality of life (QoL). Few studies have investigated the impact of glaucoma on patients’ QoL in comparison to other chronic diseases observed in patients with similar demographics. We performed a systematic literature search to assess QoL in glaucoma, osteoporosis, type 2 diabetes mellitus, and dementia.

**METHODS:** We searched MEDLINE, BIOSIS, EMBASE, and Cochrane databases. **RESULTS:** A total of 146 QoL publications were identified (some reported >1 instrument): Short-Form Health Survey (SF)-36 was used in 23 (PVL = 2; CVL = 21), SF-12 in 6 (PVL = 1; CVL = 5), National Eye Institute Visual Function Questionnaire (NEI-VFQ)-25 in 11 (PVL = 4; CVL = 7), NEI-VFQ-39 in 9 (PVL = 1; CVL = 8), NEI-VFQ-25 in 36 (PVL = 11; CVL = 25), EuroQol EQ-5D in 3 (PVL = 1; CVL = 2), Visual Function-14 (VF-14) in 20 (PVL = 1; CVL = 19), Sickness Impact Profile (SIP) in 4 (PVL = 2; CVL = 2; 1 study); CVL = 2), and Impact of Vision Impairment (IVI) in 1 (including 3 diseases: glaucoma, retinopathy [PVL] and ARMD [CVL]). By SF-36, vitality was impacted most in PVL. By SF-36 and SF-12, generally, mental health domains were affected more in PVL than CVL; physical domains were affected most in CVL. Mental aspects of QoL were affected more in PVL than CVL in all NEI-VFQ studies; ARMD and glaucoma impacted different domains. QoL was generally lower in glaucoma than ARMD, although results varied amongst studies. By EQ-SD, QoL in PVL and CVL were similarly affected. By VF-14 and SIP, CVL impacted QoL slightly more than PVL. By SIP, psychosocial and physical domains were affected equally in PVL. In the IVI study, PVL affected QoL slightly more than CVL (except glaucoma on the social scale).

**CONCLUSION:** Results showed in general, PVL and CVL disorders have a significant impact on QoL. More QoL research towards better understanding patients’ concerns with their PVL and CVL disorders are warranted.

**COMPARISON OF THE QUALITY OF LIFE IMPACT OF PERIPHERAL VISION LOSS VERSUS CENTRAL VISION LOSS**

Wait JG1, Evans K2, Hansen JE1

1Allergan Inc, Irvine, CA, USA, 2Wolters Kluwer Health, Chester, UK

**OBJECTIVE:** Vision disorders have a negative impact on quality of life (QoL). While the impairment of QoL in central-vision loss (CVL) disorders, e.g. age-related macular degeneration (ARMD), is widely acknowledged, the QoL impact of peripheral-vision loss (PVL) disorders, e.g. glaucoma, is less well-known. We performed a systematic literature search to assess the effect on QoL of PVL versus CVL.

**METHODS:** We searched MEDLINE, BIOSIS, EMBASE, and Cochrane databases. **RESULTS:** A total of 87 publications were identified (some reported >1 instrument): Short-Form Health Survey (SF)-36 was used in 23 (PVL = 2; CVL = 21), SF-12 in 6 (PVL = 1; CVL = 5), National Eye Institute Visual Function Questionnaire (NEI-VFQ)-25 in 11 (PVL = 4; CVL = 7), NEI-VFQ-39 in 9 (PVL = 1; CVL = 8), NEI-VFQ-25 in 36 (PVL = 11; CVL = 25), EuroQol EQ-5D in 3 (PVL = 1; CVL = 2), Visual Function-14 (VF-14) in 20 (PVL = 1; CVL = 19), Sickness Impact Profile (SIP) in 4 (PVL = 2; CVL = 2; 1 study); CVL = 2), and Impact of Vision Impairment (IVI) in 1 (including 3 diseases: glaucoma, retinopathy [PVL] and ARMD [CVL]). By SF-36, vitality was impacted most in PVL. By SF-36 and SF-12, generally, mental health domains were affected more in PVL than CVL; physical domains were affected most in CVL. Mental aspects of QoL were affected more in PVL than CVL in all NEI-VFQ studies; ARMD and glaucoma impacted different domains. QoL was generally lower in glaucoma than ARMD, although results varied amongst studies. By EQ-SD, QoL in PVL and CVL were similarly affected. By VF-14 and SIP, CVL impacted QoL slightly more than PVL. By SIP, psychosocial and physical domains were affected equally in PVL. In the IVI study, PVL affected QoL slightly more than CVL (except glaucoma on the social scale).

**CONCLUSION:** Results showed in general, PVL and CVL disorders have a significant impact on QoL. More QoL research towards better understanding patients’ concerns with their PVL and CVL disorders are warranted.

**MAPPING THE DERMATOLOGY QUALITY OF LIFE INDEX (DLQI) TO HEALTH-RELATED UTILITY VIA THE SF-12 IN SUBJECTS WITH ECZEMA**

Currie CJ1, Sidhu M2, Poole CD3

1Cardiff University, Cardiff, UK, 2Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 3Pharmatelligence, Cardiff, South Glamorgan, UK

**OBJECTIVE:** The purpose of this study was to conduct a statistical mapping between patient reported disease-specific quality of...